The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News in Numbers
Data: News in Numbers
$2.5bn
US politicians have requested $2.5bn in emergency funds to combat COVID-19 in the country.
5.1
The average number of days before people started showing signs of COVID-19, according to a new study .
5.1
114
The number of countries with reported cases of COVID-19 when the WHO declared a pandemic.
$4bn
According to GlobalData, Amgen and Allergan’s rituximab biosimilar could reach almost $4bn in sales by 2025.
Seven
The number of known coronaviruses that can infect people according to the US CDC.
Data: News in Numbers
5.1
The average number of days before people started showing signs of COVID-19, according to a new study
$2.5bn
US politicians have requested $2.5bn in emergency funds to combat COVID-19 in the country
114
The number of countries with reported cases of COVID-19 when the WHO declared a pandemic
$4bn
According to GlobalData, Amgen and Allergan’s rituximab biosimilar could reach almost $4bn in sales by 2025.
Seven
The number of known coronaviruses that can infect people according to the US CDC
FDA halt of foreign inspections may delay some new product approvals
The US FDA has decided to halt inspections of all foreign drug manufacturers after earlier putting inspections in China on hold.
Source: Fierce Pharma
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubt
Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had failed a phase IIb trial.
Source: Pharmaphorum
Drug shortage fears as India limits exports
The world's biggest supplier of generic drugs has restricted exports of 26 ingredients and the medicines made from them in response to the outbreak of COVID-19.
Source: BBC
Commonly prescribed Alzheimer’s drugs affect activity of another
TauRx Therapeutics have published a study in an Alzheimer’s disease mouse model which demonstrates that drugs currently used to manage the symptoms of the disease interfere with the activity of a drug with an entirely unrelated mode of action.
Source: Pharma Field
Approvals
fremanezumab (Ajovy®)
The UK’s National Institute for Health and Care Excellence has recommended Teva’s Ajovy for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.
Source: Pharma Times
Isturisa (osilodrostat) tablets
Novartis has received FDA approval for its Isturisa oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.
Source: FDA
Venclyxto (venetoclax)
The European Commission has approved Venclyxto in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
Source: Pharma Times
Sarclisa (isatuximab-irfc) Injection
The US FDA has approved Sanofi’s Sarclisa, a CD38-directed cytolytic antibody indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients multiple myeloma.
Source: PM Live